ALGS
Price:
$20.04
Market Cap:
$69.42M
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, i...[Read more]
Industry
Biotechnology
IPO Date
2020-10-16
Stock Exchange
NASDAQ
Ticker
ALGS
According to Aligos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.76. This represents a change of 321.53% compared to the average of -0.65 of the last 4 quarters.
The mean historical PE Ratio of Aligos Therapeutics, Inc. over the last ten years is -174.17. The current -2.76 PE Ratio has changed 58.47% with respect to the historical average. Over the past ten years (40 quarters), ALGS's PE Ratio was at its highest in in the June 2024 quarter at 2.85. The PE Ratio was at its lowest in in the March 2018 quarter at -564.11.
Average
-174.17
Median
-123.97
Minimum
-564.11
Maximum
-4.71
Discovering the peaks and valleys of Aligos Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 39.72%
Maximum Annual PE Ratio = -4.71
Minimum Annual Increase = -88.51%
Minimum Annual PE Ratio = -564.11
Year | PE Ratio | Change |
---|---|---|
2023 | -4.71 | -55.53% |
2022 | -10.59 | -88.51% |
2021 | -92.16 | -57.66% |
2020 | -217.66 | 39.72% |
2019 | -155.79 | -72.38% |
The current PE Ratio of Aligos Therapeutics, Inc. (ALGS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-35.82
5-year avg
-96.18
10-year avg
-174.17
Aligos Therapeutics, Inc.’s PE Ratio is less than CytomX Therapeutics, Inc. (5.48), less than Spero Therapeutics, Inc. (21.41), greater than Neoleukin Therapeutics, Inc. (-5.86), less than Instil Bio, Inc. (-2.26), less than NextCure, Inc. (-0.57), less than Assembly Biosciences, Inc. (-2.34), less than Achilles Therapeutics plc (-0.64), less than Nuvation Bio Inc. (-1.44),
Company | PE Ratio | Market cap |
---|---|---|
5.48 | $69.65M | |
21.41 | $63.24M | |
-5.86 | $8.20M | |
-2.26 | $170.65M | |
-0.57 | $33.33M | |
-2.34 | $95.60M | |
-0.64 | $43.57M | |
-1.44 | $942.39M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aligos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aligos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aligos Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Aligos Therapeutics, Inc. (ALGS)?
What is the highest PE Ratio for Aligos Therapeutics, Inc. (ALGS)?
What is the 3-year average PE Ratio for Aligos Therapeutics, Inc. (ALGS)?
What is the 5-year average PE Ratio for Aligos Therapeutics, Inc. (ALGS)?
How does the current PE Ratio for Aligos Therapeutics, Inc. (ALGS) compare to its historical average?